Allgens Medical Technology Co., Ltd. 2025 Annual Report Data Correction: Gross Profit Margin of Dental Implants Turns from Decline to Rise

Source: Allgens Medical's Correction Announcement on the 2025 Annual Report

DentalGoodNews｜July 22, 2026 - Allgens Medical Technology Co., Ltd. (688613.SH, hereinafter referred to as "Allgens Medical") issued a correction announcement regarding its 2025 Annual Report, amending the previously disclosed year-over-year changes in gross profit margins for certain products. Among these, the year-over-year change in the gross profit margin for dental implants was corrected from a decrease of 39.74 percentage points to an increase of 19.51 percentage points.

The announcement shows that Allgens Medical's dental implants achieved operating revenue of RMB 2.7492 million in 2025, a year-over-year increase of 10.68%; operating costs were RMB 1.3309 million, a year-over-year decrease of 21.12%; and the gross profit margin was 51.59%. This correction only applies to the "year-over-year change in gross profit margin" data for this product, while figures for operating revenue, operating costs, and the current gross profit margin remain unchanged.

Source: Allgens Medical's Correction Announcement on the 2025 Annual Report

Another oral product of the company, CiBei (Aojing Medical Dental Regeneration Brand), achieved operating revenue of RMB 12.0309 million in 2025, a year-over-year decrease of 69.40%; operating costs were RMB 6.8699 million, a year-over-year decrease of 51.83%; and the gross profit margin was 42.90%, a decrease of 20.83 percentage points compared to the previous year. The data related to CiBei remained unchanged before and after this correction. Compared to 2024, CiBei's operating revenue dropped from RMB 39.3215 million to RMB 12.0309 million, and the gross profit margin fell from 63.73% to 42.90%.

Source: Allgens Medical's Correction Announcement on the 2025 Annual Report

In terms of regional performance, the North China region recorded operating revenue of RMB 31.5959 million in 2025, with a gross profit margin of 70.04%, a decrease of 5.70 percentage points year-over-year. Overseas business achieved revenue of RMB 200,200, with a gross profit margin increase of 280.44 percentage points year-over-year. Previously, in February 2026, Allgens Medical issued a correction announcement for its 2025 Performance Forecast, revising the Net Profit Attributable to Shareholders of the Parent Company after deducting non-recurring gains and losses to a loss of RMB 915,000.

The company stated that a post-review revealed some information errors; aside from this correction, the rest of the "2025 Annual Report" remains unchanged. The company extends its sincere apologies for any inconvenience caused to investors by this correction and stated that it will strengthen proofreading efforts during the periodic report preparation process to improve the quality of information disclosure.